PSTV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PSTV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Plus Therapeutics's Capital Expenditure for the three months ended in Dec. 2023 was $-0.04 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $-1.88 Mil.
GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.
The historical data trend for Plus Therapeutics's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
Plus Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Plus Therapeutics's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Plus Therapeutics's Capex-to-Operating-Cash-Flow falls into.
Plus Therapeutics's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (-0.16) | / | -12.851 | |
= | N/A |
Plus Therapeutics's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (-0.042) | / | -1.881 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics (NAS:PSTV) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Thank you for viewing the detailed overview of Plus Therapeutics's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Marc H Hedrick | officer: President | C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
Robert P Lenk | director | LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060 |
Howard Clowes | director | 217 DWIGHT ROAD, BURLINGAME CA 94010 |
Greg Petersen | director | 3100 MAIN STREET, SUITE 900, HOUSTON TX 77002 |
Sims Andrew John Hugh Macintyre | officer: Chief Financial Officer | 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756 |
Norman D. Lafrance | officer: CHIEF MEDICAL OFFICER | MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142 |
Es-johansson An Van | director | 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736 |
Ag Postfinance | 10 percent owner | MINGERSTRASSE 20, BERN V8 3030 |
Bank Sa Swissquote | 10 percent owner | CHEMIN DE LA CRETAUX 33, GLAND V8 1196 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Ron Martell | director | PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
Mark Marino | officer: Chief Medical Officer | C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
John David Harris | officer: VP and GM of Cell Therapy | 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
Gail K Naughton | director | C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
David Rickey | director |
From GuruFocus
By Marketwired • 10-10-2023
By Marketwired • 10-31-2023
By sperokesalga sperokesalga • 06-01-2023
By sperokesalga sperokesalga • 05-12-2023
By Marketwired • 08-11-2023
By Marketwired • 10-09-2023
By Marketwired • 07-13-2023
By Marketwired • 10-23-2023
By Marketwired • 09-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.